SCM
ACRS icon

Stonepine Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Stonepine Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-192,900
Closed -$367K – 68
2025
Q3 		$367K Sell
192,900
-298,400
-61% -$520K 0.3% 48
2025
Q2 		$698K Sell
491,300
-36,542
-7% -$49.4K 0.68% 35
2025
Q1 		$2.77M Sell
527,842
-135,563
-20% -$289K 2.69% 13
2024
Q4 		$1.65M Sell
663,405
-1,795,468
-73% -$4.47M 1.33% 23
2024
Q3 		$2.83M Buy
2,458,873
+531,427
+28% +$652K 1.79% 19
2024
Q2 		$2.12M Buy
+1,927,446
New +$2.26M 1.93% 11

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Stonepine Capital Management's ACRS Position: Q4 2025 in Review

Stonepine Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2025, closing a stake of 192,900 shares — an estimated $367K sold.

Stonepine Capital Management first reported a position in ACRS in Q2 2024 and held it in 6 quarters. The position peaked at $2.83M in Q3 2024. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Stonepine Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 192,900 Aclaris Therapeutics shares in Q4 2025, an estimated $367K.
  • Stonepine Capital Management first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 6 quarters.
  • Stonepine Capital Management's Aclaris Therapeutics position peaked at $2.83M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.